SCHEMBL4242289

SCHEMBL4242289

Nc1ccc(NC(=O)[C@@H](N)CCC(=O)O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 10/20 0.61
S1PR1 P21453 1/20 0.59
S1PR3 Q99500 1/20 0.59
MMP2 P08253 1/20 0.50
MMP9 P14780 1/20 0.50
MAPT P10636 1/20 0.47
RAB9A P51151 1/20 0.47
GRM8 O00222 1/20 0.44
GRM6 O15303 1/20 0.44
GRIN2D O15399 1/20 0.44
GRIN3B O60391 1/20 0.44
GSR P00390 1/20 0.44
CYP1A2 P05177 1/20 0.44
GRIK1 P39086 1/20 0.44
GRM5 P41594 1/20 0.44
GRIA1 P42261 1/20 0.44
GRIA2 P42262 1/20 0.44
GRIA3 P42263 1/20 0.44
SLC1A3 P43003 1/20 0.44
SLC1A2 P43004 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4242300 0.87 LTA4H (0.48) LTA4HS1PR1S1PR3MAPTRAB9A
SCHEMBL20243040 0.87 LTA4H (0.68) LTA4HS1PR1S1PR3MMP2MMP9
SCHEMBL2522626 0.87 LTA4H (0.68) LTA4HS1PR1S1PR3MMP2MMP9
SCHEMBL11038421 0.86 LTA4H (0.60) LTA4HS1PR1S1PR3MMP2MMP9
SCHEMBL7902676 0.86 LTA4H (0.60) LTA4HS1PR1S1PR3MMP2MMP9
SCHEMBL23125177 0.84 LTA4H (0.62) LTA4HS1PR1S1PR3MMP2MMP9
SCHEMBL23125175 0.84 LTA4H (0.62) LTA4HS1PR1S1PR3MMP2MMP9
SCHEMBL19234506 0.83 S1PR1 (0.62) LTA4HS1PR1S1PR3MMP2MMP9
SCHEMBL1261530 0.83 BCHE (0.57) LTA4HS1PR1S1PR3MMP2MMP9
SCHEMBL20715658 0.82 LTA4H (0.60) LTA4HS1PR1S1PR3MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315973-A1 PARP-1 INHIBITORS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2014-10-23 US disclosed
WO-2013052006-A1 PARP-1 INHIBITORS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) 2013-04-11 WO disclosed
US-7481781-B2 Ultrasound therapy GENDEL LIMITED (GB) 2009-01-27 US disclosed
EP-1506039-B1 ABLATION DEVICE GENDEL LTD (GB) 2008-10-29 EP disclosed
WO-2006044716-A2 CELL PERMEABLE NANOCONJUGATES OF SHELL-CROSSLINKED KNEDEL (SCK) AND PEPTIDE NUCLEIC ACIDS ('PNAs') WITH UNIQUELY EXPRESSED OR OVER-EXPRESSED mRNA TARGETING SEQUENCES FOR EARLY DIAGNOSIS AND THERAPY OF CANCER WASHINGTON UNIVERSITY IN ST.LOUIS (US) 2006-04-27 WO disclosed
EP-1196143-B1 USE OF AN ELECTRIC FIELD FOR SENSITISING RED BLOOD CELLS TO ULTRASOUND UUTECH LTD (GB) 2006-03-01 EP disclosed
US-20050043726-A1 Device II GENDEL LIMITED (GB) 2005-02-24 US disclosed
US-6821274-B2 DISRUPTING DISEASED AREA WHILE MINIMIZING HARM TO NEIGHBORING HEALTHY CELLS; PRETREATMENT WITH ELECTRIC FIELD GENDEL LTD. (IE) 2004-11-23 US disclosed
US-6812204-B1 ELECTROSENSITIZING RED BLOOD CELL; APPLYING SOUND WAVES GENDEL LIMITED (GB) 2004-11-02 US disclosed
WO-2004083391-A2 TARGETED AND REGIONAL CELLULAR ABLATION IN ZEBRAFISH WASHINGTON UNIVERSITY IN ST. LOUIS (US) 2004-09-30 WO disclosed
EP-1253912-A1 APPARATUS FOR PROVIDING A RED BLOOD CELL CARRIER Gendel Limited (GB) 2002-11-06 EP disclosed
US-20020151004-A1 Delivery vehicles and methods for using the same CRAIG ROGER (GB) 2002-10-17 US disclosed
WO-2002007752-A2 RED BLOOD CELL AS VEHICLE FOR AGENT-MEMBRANE TRANSLOCATION SEQUENCE CONJUGATE GENDEL LIMITED (GB) 2002-01-31 WO disclosed
US-20020009706-A1 Method for loading cells with an agent MCHALE ANTHONY P (IE) 2002-01-24 US disclosed
US-20010053549-A1 Loading method GENDEL LIMITED (GB) 2001-12-20 US disclosed
US-20010031499-A1 Loading system and method for using the same GENDEL LIMITED (GB) 2001-10-18 US disclosed
WO-2001058432-A1 APPARATUS FOR PROVIDING A RED BLOOD CELL CARRIER GENDEL LIMITED (GB) 2001-08-16 WO disclosed
US-20010008758-A1 Delivery of an agent UUTECH LIMITED (GB) 2001-07-19 US disclosed
EP-0970232-A2 NON-IMMUNOGENIC PRODRUGS AND SELECTABLE MARKERS FOR USE IN GENE THERAPY Chiron Corporation (US) 2000-01-12 EP disclosed
WO-1998030709-A2 NON-IMMUNOGENIC PRODRUGS AND SELECTABLE MARKERS FOR USE IN GENE THERAPY CHIRON CORPORATION (US) 1998-07-16 WO disclosed